Ultimovacs ASA Reports Fourth Quarter 2023 Financial Results and Provides General Business Update
February 14, 2024 01:00 ET
|
Ultimovacs ASA
Readout of topline result expected in March 2024 from UV1 randomized Phase II trial INITIUM in Ultimovacs’ lead indication, advanced malignant melanomaTopline result will report primary endpoint of...
Ultimovacs ASA: Invitation to fourth quarter 2023 results webcast presentation
February 08, 2024 02:00 ET
|
Ultimovacs ASA
Oslo, February 8, 2023: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology leader in novel immunotherapeutic cancer vaccines, invites to a webcast presentation of its fourth...
Ultimovacs Receives FDA Fast Track Designation for UV1 Cancer Vaccine for the Treatment of Patients with Unresectable Mesothelioma
February 05, 2024 01:00 ET
|
Ultimovacs ASA
Fast Track designation is granted for UV1 in combination with ipilimumab and nivolumab for the treatment of patients with unresectable malignant pleural mesothelioma to improve overall...
Ultimovacs Updates Timeline for Reporting on Randomized UV1 Phase II Trial INITIUM in Malignant Melanoma; Topline Results expected in March 2024
January 16, 2024 01:00 ET
|
Ultimovacs ASA
Study protocol enables readout of the INITIUM trial after all patients have been followed for a minimum of 18 months, or after 70 patients have progressed or died.As of today, the 70 events...
Ultimovacs ASA: Mandatory notification of trade by primary insider
January 04, 2024 12:57 ET
|
Ultimovacs ASA
Oslo, 4 January 2024: Carlos de Sousa, Chief Executive Officer and primary insider in Ultimovacs ASA, has today bought 500 shares in the company at an average price of NOK 130.00 per share. Following...
Ultimovacs ASA: Mandatory notification of trade by primary insider
January 02, 2024 13:25 ET
|
Ultimovacs ASA
Oslo, 2 January 2024: Carlos de Sousa, Chief Executive Officer and primary insider in Ultimovacs ASA, has today bought 1,500 shares in the company at an average price of NOK 119.75 per share. In...
Ultimovacs ASA: Mandatory notification of trade by primary insider
December 19, 2023 10:51 ET
|
Ultimovacs ASA
Oslo, 19 December 2023, a closely related party of Carlos de Sousa, Chief Executive Officer and primary insider in Ultimovacs ASA, has today bought 1,000 shares in the company at an average price of...
Ultimovacs Announces Completion of Exploratory Phase I TENDU Study of TET Vaccine Technology Platform Meeting the Primary Endpoint
December 18, 2023 01:00 ET
|
Ultimovacs ASA
Dose-escalation, first-in-human Phase I trial showed good safety and tolerability across all dose-cohorts, meeting the primary endpointData included observations of immune activation with...
Ultimovacs Announces Resignation of Aitana Peire from Board of Directors
November 28, 2023 01:00 ET
|
Ultimovacs ASA
Oslo, November 28, 2023: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical-stage biotechnology leader in novel immunotherapeutic cancer vaccines, today announces that Aitana Peire, Ph.D., has...
Ultimovacs ASA: Mandatory notification of trade by primary insider
November 21, 2023 11:00 ET
|
Ultimovacs ASA
Oslo, 21 November 2023, a closely related party of Carlos de Sousa, Chief Executive Officer and primary insider in Ultimovacs ASA, has today bought 500 shares in the company at an average price of NOK...